The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women

L Elaine Waetjen, Jeanette S. Brown, Eric Vittinghoff, Kristine E. Ensrud, JoAnn Pinkerton, Robert Wallace, Judith L. Macer, Deborah Grady

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

OBJECTIVE: To estimate the effect of 2 years of treatment with ultralow-dose transdermal estradiol (E2) on incontinence in postmenopausal women. METHODS: Ultra Low Dose Transdermal estRogen Assessment (ULTRA) was a multicenter, randomized, double-blinded, placebo-controlled trial of unopposed ultralow-dose (0.014 mg/d) transdermal E2 for prevention of osteoporosis in 417 postmenopausal women aged 60 to 80 years. Frequency of incontinence episodes was assessed at baseline and after 4 months and 2 years of treatment using a self-reported questionnaire. We used an intention-to-treat analysis to compare change in incontinence frequency, improved (decreased 2 or more episodes per week), unchanged (increased or decreased no more than 1 episode per week), or worsened (increased 2 or more episodes per week) between the E2 and placebo groups among women with and without at least weekly incontinence at baseline. RESULTS: At baseline, the prevalence of at least weekly incontinence was similar between E2 and placebo groups (43%). After 2 years, there was no difference between groups in the proportions of women with incontinence at baseline whose incontinence improved, worsened, or was unchanged. The odds ratio for worsening incontinence in the E2 compared with placebo group was 1.35 (95% confidence interval 0.75-2.42. In women without incontinence at baseline, the odds of developing at least weekly incontinence after 2 years in the E2 compared with placebo group was not significant (odds ratio 1.2, 95% confidence interval 0.7-2.2). CONCLUSION: Two years of treatment with unopposed ultralow-dose transdermal E2 did not substantially change the frequency of incontinence symptoms or alter the risk of developing at least weekly incontinence.

Original languageEnglish (US)
Pages (from-to)946-952
Number of pages7
JournalObstetrics and Gynecology
Volume106
Issue number5 I
StatePublished - Nov 2005

Fingerprint

Urinary Incontinence
Estradiol
Placebos
Odds Ratio
Confidence Intervals
Intention to Treat Analysis
Osteoporosis
Estrogens
Therapeutics

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Waetjen, L. E., Brown, J. S., Vittinghoff, E., Ensrud, K. E., Pinkerton, J., Wallace, R., ... Grady, D. (2005). The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women. Obstetrics and Gynecology, 106(5 I), 946-952.

The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women. / Waetjen, L Elaine; Brown, Jeanette S.; Vittinghoff, Eric; Ensrud, Kristine E.; Pinkerton, JoAnn; Wallace, Robert; Macer, Judith L.; Grady, Deborah.

In: Obstetrics and Gynecology, Vol. 106, No. 5 I, 11.2005, p. 946-952.

Research output: Contribution to journalArticle

Waetjen, LE, Brown, JS, Vittinghoff, E, Ensrud, KE, Pinkerton, J, Wallace, R, Macer, JL & Grady, D 2005, 'The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women', Obstetrics and Gynecology, vol. 106, no. 5 I, pp. 946-952.
Waetjen LE, Brown JS, Vittinghoff E, Ensrud KE, Pinkerton J, Wallace R et al. The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women. Obstetrics and Gynecology. 2005 Nov;106(5 I):946-952.
Waetjen, L Elaine ; Brown, Jeanette S. ; Vittinghoff, Eric ; Ensrud, Kristine E. ; Pinkerton, JoAnn ; Wallace, Robert ; Macer, Judith L. ; Grady, Deborah. / The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women. In: Obstetrics and Gynecology. 2005 ; Vol. 106, No. 5 I. pp. 946-952.
@article{5b55626a6dec4aa7aca4038f31d46119,
title = "The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women",
abstract = "OBJECTIVE: To estimate the effect of 2 years of treatment with ultralow-dose transdermal estradiol (E2) on incontinence in postmenopausal women. METHODS: Ultra Low Dose Transdermal estRogen Assessment (ULTRA) was a multicenter, randomized, double-blinded, placebo-controlled trial of unopposed ultralow-dose (0.014 mg/d) transdermal E2 for prevention of osteoporosis in 417 postmenopausal women aged 60 to 80 years. Frequency of incontinence episodes was assessed at baseline and after 4 months and 2 years of treatment using a self-reported questionnaire. We used an intention-to-treat analysis to compare change in incontinence frequency, improved (decreased 2 or more episodes per week), unchanged (increased or decreased no more than 1 episode per week), or worsened (increased 2 or more episodes per week) between the E2 and placebo groups among women with and without at least weekly incontinence at baseline. RESULTS: At baseline, the prevalence of at least weekly incontinence was similar between E2 and placebo groups (43{\%}). After 2 years, there was no difference between groups in the proportions of women with incontinence at baseline whose incontinence improved, worsened, or was unchanged. The odds ratio for worsening incontinence in the E2 compared with placebo group was 1.35 (95{\%} confidence interval 0.75-2.42. In women without incontinence at baseline, the odds of developing at least weekly incontinence after 2 years in the E2 compared with placebo group was not significant (odds ratio 1.2, 95{\%} confidence interval 0.7-2.2). CONCLUSION: Two years of treatment with unopposed ultralow-dose transdermal E2 did not substantially change the frequency of incontinence symptoms or alter the risk of developing at least weekly incontinence.",
author = "Waetjen, {L Elaine} and Brown, {Jeanette S.} and Eric Vittinghoff and Ensrud, {Kristine E.} and JoAnn Pinkerton and Robert Wallace and Macer, {Judith L.} and Deborah Grady",
year = "2005",
month = "11",
language = "English (US)",
volume = "106",
pages = "946--952",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "5 I",

}

TY - JOUR

T1 - The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women

AU - Waetjen, L Elaine

AU - Brown, Jeanette S.

AU - Vittinghoff, Eric

AU - Ensrud, Kristine E.

AU - Pinkerton, JoAnn

AU - Wallace, Robert

AU - Macer, Judith L.

AU - Grady, Deborah

PY - 2005/11

Y1 - 2005/11

N2 - OBJECTIVE: To estimate the effect of 2 years of treatment with ultralow-dose transdermal estradiol (E2) on incontinence in postmenopausal women. METHODS: Ultra Low Dose Transdermal estRogen Assessment (ULTRA) was a multicenter, randomized, double-blinded, placebo-controlled trial of unopposed ultralow-dose (0.014 mg/d) transdermal E2 for prevention of osteoporosis in 417 postmenopausal women aged 60 to 80 years. Frequency of incontinence episodes was assessed at baseline and after 4 months and 2 years of treatment using a self-reported questionnaire. We used an intention-to-treat analysis to compare change in incontinence frequency, improved (decreased 2 or more episodes per week), unchanged (increased or decreased no more than 1 episode per week), or worsened (increased 2 or more episodes per week) between the E2 and placebo groups among women with and without at least weekly incontinence at baseline. RESULTS: At baseline, the prevalence of at least weekly incontinence was similar between E2 and placebo groups (43%). After 2 years, there was no difference between groups in the proportions of women with incontinence at baseline whose incontinence improved, worsened, or was unchanged. The odds ratio for worsening incontinence in the E2 compared with placebo group was 1.35 (95% confidence interval 0.75-2.42. In women without incontinence at baseline, the odds of developing at least weekly incontinence after 2 years in the E2 compared with placebo group was not significant (odds ratio 1.2, 95% confidence interval 0.7-2.2). CONCLUSION: Two years of treatment with unopposed ultralow-dose transdermal E2 did not substantially change the frequency of incontinence symptoms or alter the risk of developing at least weekly incontinence.

AB - OBJECTIVE: To estimate the effect of 2 years of treatment with ultralow-dose transdermal estradiol (E2) on incontinence in postmenopausal women. METHODS: Ultra Low Dose Transdermal estRogen Assessment (ULTRA) was a multicenter, randomized, double-blinded, placebo-controlled trial of unopposed ultralow-dose (0.014 mg/d) transdermal E2 for prevention of osteoporosis in 417 postmenopausal women aged 60 to 80 years. Frequency of incontinence episodes was assessed at baseline and after 4 months and 2 years of treatment using a self-reported questionnaire. We used an intention-to-treat analysis to compare change in incontinence frequency, improved (decreased 2 or more episodes per week), unchanged (increased or decreased no more than 1 episode per week), or worsened (increased 2 or more episodes per week) between the E2 and placebo groups among women with and without at least weekly incontinence at baseline. RESULTS: At baseline, the prevalence of at least weekly incontinence was similar between E2 and placebo groups (43%). After 2 years, there was no difference between groups in the proportions of women with incontinence at baseline whose incontinence improved, worsened, or was unchanged. The odds ratio for worsening incontinence in the E2 compared with placebo group was 1.35 (95% confidence interval 0.75-2.42. In women without incontinence at baseline, the odds of developing at least weekly incontinence after 2 years in the E2 compared with placebo group was not significant (odds ratio 1.2, 95% confidence interval 0.7-2.2). CONCLUSION: Two years of treatment with unopposed ultralow-dose transdermal E2 did not substantially change the frequency of incontinence symptoms or alter the risk of developing at least weekly incontinence.

UR - http://www.scopus.com/inward/record.url?scp=27444441576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27444441576&partnerID=8YFLogxK

M3 - Article

C2 - 16260511

AN - SCOPUS:27444441576

VL - 106

SP - 946

EP - 952

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 5 I

ER -